

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	<u>General</u>
AstraZeneca (durvalumab,	All Wales Therapeutics and Toxicology
tremelimumab)	Centre
	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
 Addenbrookes Liver Transplant 	Wales
Association	British National Formulary
Black Health Agency for Equality	Care Quality Commission
British Liver Trust	Department of Health, Social Services
Cancer Black Care	and Public Safety for Northern Ireland
Cancer Equality	Healthcare Improvement Scotland
Cancer 52	Medicines and Healthcare products
GUTS UK	Regulatory Agency
Haemochromatosis UK	National Association of Primary Care
Helen Rollason Cancer Charity	National Pharmacy Association
Independent Cancer Patients' Voice	NHS Confederation
Liver4Life	Scottish Medicines Consortium
Macmillan Cancer Support	Welsh Government
Maggie's Centres	Welsh Health Specialised Services
Marie Curie	Committee
	Committee
Pelican Cancer Foundation Canth Asian Haalth Farm define	Possible comparator companies
South Asian Health Foundation South Asian Health Foundation	Bayer (sorafenib)
Specialised Healthcare Alliance	
Tenovus Cancer Care	Boston Scientific (TheraSphere) Calltrian Llaghbages (havesigueseb)
The Hepatitis C Trust	Celltrion Healthcare (bevacizumab) Pr. Boddy's Laboratorias
	Dr. Reddy's Laboratories
Healthcare professional groups	(bevacizumab)
Association of Anaesthetists of Great	Eisai (lenvatinib)
Britain & Ireland	Organon Pharma (bevacizumab)
Association of Cancer Physicians	Pfizer (bevacizumab)
Association of Surgeons of Great	Roche (atezolizumab, bevacizumab)
Britain & Ireland	Sandoz (sorafenib)
British Association of the Study of the	Sirtex (SIR-Spheres)
Liver (BASL) / HCC UK	Terumo Europe (QuirumSpheres)
British Geriatrics Society	 Thornton and Ross (bevacizumab,
British Institute of Radiologists	sorafenib)

Final stakeholder list for the appraisal of durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]



Provisional Consultees Provisional Commentators (no right to submit or appeal) Zentiva (bevacizumab, sorafenib) **British Oncology Pharmacy** Association British Psychosocial Oncology Society Relevant research groups British Society of Gastroenterology Cochrane Hepato-biliary Group Cochrane Infectious Diseases Group Cancer Research UK Hepatitis Nurse Specialist Forum Cochrane UK Foundation for Liver Research Royal College of Anaesthetists Royal College of General Practitioners Genomics England Royal College of Nursing Institute of Cancer Research MRC Clinical Trials Unit Royal College of Pathologists Royal College of Physicians National Institute for Health Research Royal College of Radiologists Associated Public Health groups Royal College of Surgeons **Public Health Wales** Royal Pharmaceutical Society UK Health Security Agency Royal Society of Medicine Society and College of Radiologists **Evidence Review Group UK Clinical Pharmacy Association** National Institute for Health Research **UK Oncology Nursing Society** Health Technology Assessment Programme (NETSCC) Others Warwick Evidence Department of Health and Social Care NHS England Associated Guideline Group NICE - National Guideline Alliance (cancer, mental health, and women and children's health)

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Final stakeholder list for the appraisal of durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]

Issue date: June 2024



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.